1. Home
  2. CRSP vs OMAB Comparison

CRSP vs OMAB Comparison

Compare CRSP & OMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$53.52

Market Cap

5.0B

Sector

Health Care

ML Signal

HOLD

Logo Grupo Aeroportuario del Centro Norte S.A.B. de C.V. ADS

OMAB

Grupo Aeroportuario del Centro Norte S.A.B. de C.V. ADS

HOLD

Current Price

$110.44

Market Cap

5.0B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRSP
OMAB
Founded
2013
1998
Country
Switzerland
Mexico
Employees
N/A
1355
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Aerospace
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
5.0B
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
CRSP
OMAB
Price
$53.52
$110.44
Analyst Decision
Buy
Buy
Analyst Count
17
4
Target Price
$70.29
$120.00
AVG Volume (30 Days)
1.6M
50.0K
Earning Date
05-11-2026
04-28-2026
Dividend Yield
N/A
4.06%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$289,590,000.00
N/A
Revenue This Year
$807.72
$8.36
Revenue Next Year
$172.52
$13.05
P/E Ratio
N/A
$21.86
Revenue Growth
9169.85
N/A
52 Week Low
$44.12
$95.69
52 Week High
$78.48
$134.99

Technical Indicators

Market Signals
Indicator
CRSP
OMAB
Relative Strength Index (RSI) 53.02 58.94
Support Level $51.55 $110.22
Resistance Level $59.83 $114.53
Average True Range (ATR) 1.80 2.83
MACD 0.64 0.58
Stochastic Oscillator 77.28 86.59

Price Performance

Historical Comparison
CRSP
OMAB

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About OMAB Grupo Aeroportuario del Centro Norte S.A.B. de C.V. ADS

Grupo Aeroportuario del Centro Norte SAB de CV operates, maintains and develops airports in the Mexico. The airport is in Monterrey, which serves nearly half of the company's total passengers. In addition, the company manages hotels, industrial parks, and individual airports. Its reportable segments include its airports, the Terminal 2 NH Collection Hotel, the Hilton Garden Inn Hotel and the OMA-VYNMSA Industrial Park, and in Others.

Share on Social Networks: